In silico and in vitro assessment of tumor mutational burden
November 2018
University Hospital Heidelberg, Heidelberg, Germany
Assessment of Tumor Mutational Burden (TMB) is essential for response stratification of cancer patients treated with immune checkpoint inhibitors. TMB approximates the number of neoantigens that potentially are recognized by the immune system. As far as now, TMB assessment has been done by whole-exome sequencing which implementation in diagnostics is hampered by tissue availability as well as time and cost constraints. In the present study, the researchers have used in silico and sequencing analysis of commercially available panels of genes in cancer patients tissues. The data suggest that TMB approximation using gene panel sequencing of tumor tissue is feasible and can be implemented in routine diagnostics.
Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels
Albrecht Stenzinger
Added on: 07-27-2021
[1] https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.32002[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
